Royalty Pharma PLC Form 4 insider transactions

Pablo G. Legorreta, CEO, Chairman of the Board and a Director of Royalty Pharma plc, reported multiple transactions in common stock on August 5, 2026.

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, reported multiple transactions in common stock on August 5, 2026.

Christopher Hite, EVP & Chairman, Partnering of Royalty Pharma plc, received 11,002 shares of common stock on August 5, 2026.

Marshall Urist, EVP, Research & Investments of Royalty Pharma plc, reported multiple transactions in common stock on August 5, 2026.

Royalty Pharma plc executive Marshall Urist reported the sale of 9,099 Class A Ordinary Shares under a pre-arranged 10b5-1 trading plan.

Royalty Pharma plc director Bonnie L. Bassler received Class A Ordinary Shares valued at $54,399.98 as part of her director compensation.

Royalty Pharma EVP Marshall Urist reported a sale of 9,098 Class A Ordinary Shares for approximately $55.18 per share, executed under a pre-arranged 10b5-1 trading plan.

Royalty Pharma plc reports a significant sale of Class A Ordinary Shares by EVP & Chairman, Partnering, Christopher Hite, executed under a pre-arranged trading plan.

Royalty Pharma plc director Elizabeth H. Weatherman was granted restricted stock units under the company's equity incentive plan.

Royalty Pharma Director Gregory Norden acquired 4,545 Class A Ordinary Shares through an award of restricted stock units.

Royalty Pharma plc reports a restricted stock unit award granted to Director Ted W. Love, vesting in one year or at the next annual meeting.

Royalty Pharma plc director David C. Hodgson acquired 4,545 Class A Ordinary Shares through an award of restricted stock units.

Royalty Pharma plc reports a transaction where Director Carole Ho acquired restricted stock units, reflecting an equity award under the company's incentive plan.

Catherine M. Engelbert, a Director at Royalty Pharma plc, received an award of restricted stock units valued at $0, with 4,545 shares vesting on a future date.

Royalty Pharma Director Vlad Coric acquired 4,545 ordinary shares through an award of restricted stock units.

Bonnie L. Bassler, a Director at Royalty Pharma plc, received an award of 4,545 Class A Ordinary Shares under the company's equity incentive plan.

EVP & CFO Terrance P. Coyne sold 64,399 Class A Ordinary Shares of Royalty Pharma plc via a pre-arranged 10b5-1 trading plan.

EVP of Research & Investments Marshall Urist sold 13,684 Class A Ordinary Shares of Royalty Pharma plc via a 10b5-1 trading plan.

EVP of Research & Investments Marshall Urist sold 13,684 Class A Ordinary Shares of Royalty Pharma plc via a 10b5-1 plan.

CEO and Chairman Pablo Legorreta acquired 143,821 Class A Ordinary Shares of Royalty Pharma plc through an equity award settlement.

Royalty Pharma EVP and CFO Terrance P. Coyne acquired 24,263 Class A Ordinary Shares through the settlement of Equity Performance Awards.

Royalty Pharma EVP and Vice Chairman Christopher Hite acquired 24,263 Class A Ordinary Shares via equity award settlement.

Royalty Pharma executive Marshall Urist acquired 18,197 Class A Ordinary Shares through the settlement of equity performance awards.

Royalty Pharma EVP & CFO Terrance P. Coyne sold 34,791 Class A Ordinary Shares via a pre-arranged 10b5-1 trading plan.

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, reported the sale of Class A Ordinary Shares valued at approximately $48.33 per share, executed under a pre-arranged 10b5-1 trading plan.

Royalty Pharma plc Director Bonnie L. Bassler acquired 815 Class A Ordinary Shares as part of her compensation plan on March 31, 2026.

Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 34,791 Class A Ordinary Shares on March 23, 2026, for a weighted average price of $45.5287 per share under a pre-arranged 10b5-1 plan.

Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 34,791 Class A Ordinary Shares for approximately $1.6 million through a pre-arranged 10b5-1 trading plan.

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, sold over 34,000 Class A Ordinary Shares for approximately $45.32 per share as part of a pre-arranged trading plan.

Royalty Pharma CEO Pablo G. Legorreta acquired 157,828 Class A Ordinary Shares through an exempt transaction related to equity performance awards.